Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Amid NIH funding delays, reversals and uncertainty, a scientist at Harvard who studies breast cancer has lost one-third of ...

Actress Angelina Jolie shares her mastectomy scars 10 years on, spotlighting genetic risk, early detection, and the ...

Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense (R) ...

A discovery in mice reveals why fasting enhances a type of breast cancer treatment — a hormone-signalling pathway and gene-expression changes have key roles. Stephen D. Hursting is in the Department ...

Welcome to the final edition of The Targeted Pulse of 2025, your weekly wrap-up of the top developments in oncology. This ...

Sacituzumab does not improve outcomes vs chemotherapy when used as the first treatment after endocrine therapy failure in HR+/HER2- advanced breast cancer, the ASCENT-07 trial finds.

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...

Tasmania's health department was aware a 32-year-old breast cancer screening bus was unsafe for years, but continued operating it up until two staff suffered electric shocks.